{"DataElement":{"publicId":"5777344","version":"1","preferredName":"Crizotinib Agent Toxicity Dose Reduced Dose Indicator","preferredDefinition":"A yes/no indicator of whether agent Crizotinib dosage was reduced due to toxicity experienced by the patient.","longName":"CZ_Tox_Ds_Rdc_Ind","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5777343","version":"1","preferredName":"Crizotinib Agent Toxicity Dose Reduced","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The finding of bodily harm due to the poisonous effects of something._An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","longName":"5731690v1.0:5777341v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5731690","version":"1","preferredName":"Crizotinib Agent","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C74061:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C213504-F0E4-65FC-E053-F662850A793C","latestVersionIndicator":"Yes","beginDate":"2017-04-01","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-01","modifiedBy":"ONEDATA","dateModified":"2017-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"5777341","version":"1","preferredName":"Toxicity Dose Reduced","preferredDefinition":"The finding of bodily harm due to the poisonous effects of something.:An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","longName":"C27990:C49505","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Toxicity","conceptCode":"C27990","definition":"The finding of bodily harm due to the poisonous effects of something.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dose Reduced","conceptCode":"C49505","definition":"An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D7972CF-B98C-606F-E053-F662850A177C","latestVersionIndicator":"Yes","beginDate":"2017-04-18","endDate":null,"createdBy":"HLAINGY","dateCreated":"2017-04-18","modifiedBy":"ONEDATA","dateModified":"2017-04-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435016","version":"1","preferredName":"Chemotherapy Regimen","preferredDefinition":"Drug therapy using two or more drugs given together or separately for a combined effect.","longName":"C12218","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B9F7-9264-25C9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D7972CF-B99D-606F-E053-F662850A177C","latestVersionIndicator":"Yes","beginDate":"2017-04-18","endDate":null,"createdBy":"HLAINGY","dateCreated":"2017-04-18","modifiedBy":"MAESKEB","dateModified":"2019-10-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2952984","version":"1","preferredName":"Dose Indicator","preferredDefinition":"the indicator for the amount of medicine taken, or radiation given, at one time.","longName":"2952984v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Yes, unplanned per protocol","valueDescription":"Yes, unplanned per protocol","ValueMeaning":{"publicId":"2952985","version":"1","preferredName":"Yes, unplanned per protocol","longName":"2952985","preferredDefinition":"Yes, unplanned per protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C341E1-52FC-6926-E040-BB89AD432CB4","latestVersionIndicator":"Yes","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75C341E1-5315-6926-E040-BB89AD432CB4","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ONEDATA","dateModified":"2009-10-12","deletedIndicator":"No"},{"value":"Yes, planned per protocol","valueDescription":"Yes, planned per protocol","ValueMeaning":{"publicId":"2952986","version":"1","preferredName":"Yes, planned per protocol","longName":"2952986","preferredDefinition":"Yes, planned per protocol","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C341E1-531F-6926-E040-BB89AD432CB4","latestVersionIndicator":"Yes","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75C341E1-5338-6926-E040-BB89AD432CB4","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ONEDATA","dateModified":"2009-10-12","deletedIndicator":"No"},{"value":"No","valueDescription":"No ","ValueMeaning":{"publicId":"2567170","version":"1","preferredName":"No","longName":"2567170","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D36F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-13","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":"Updated to add NCIt concept relationship. Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":"2022.12.29 Alt VM added per ticket request CADSR0001837. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"75C341E1-5342-6926-E040-BB89AD432CB4","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ONEDATA","dateModified":"2009-10-12","deletedIndicator":"No"},{"value":"N/A","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5682946","version":"1","preferredName":"Not Applicable","longName":"5682946v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9B2B-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":"2023.8.15 Alt VM added per ticket request CADSR0002731. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6BAB45A-987B-42A8-E053-4EBD850A5197","beginDate":"2020-05-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-05-28","modifiedBy":"ONEDATA","dateModified":"2020-05-28","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A6BAB45A-9886-42A8-E053-4EBD850A5197","beginDate":"2020-05-28","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2020-05-28","modifiedBy":"ONEDATA","dateModified":"2020-05-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2952983","version":"1","preferredName":"Dose Indicator","preferredDefinition":"The amount of medicine taken, or radiation given, at one time.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C25488:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C341E1-52D6-6926-E040-BB89AD432CB4","latestVersionIndicator":"Yes","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ONEDATA","dateModified":"2009-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75C341E1-52E7-6926-E040-BB89AD432CB4","latestVersionIndicator":"Yes","beginDate":"2009-10-12","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-10-12","modifiedBy":"ZHANGWE","dateModified":"2020-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Was Crizotinib dose reduced d","type":"Preferred Question Text","description":"Was Crizotinib dose reduced due to toxicity during this reporting period?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D798C96-DDDB-2921-E053-F662850AB031","latestVersionIndicator":"Yes","beginDate":"2017-04-18","endDate":null,"createdBy":"HLAINGY","dateCreated":"2017-04-18","modifiedBy":"LAMEMIL","dateModified":"2021-12-29","changeDescription":"Workflow and Registration Status Changed per Brenda Duggan; 05.16.18 CDE definition updated EL 12/29/2021","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}